1.Effect of Ginsenoside-Rg combined with oxaliplatin and sorafenib on hepatic carcinoma cell apoptosis
Jianxun BAO ; Haofei WANG ; Yunjuan HUANG
Chinese Journal of Biochemical Pharmaceutics 2014;(1):41-42,45
Objective To discuss the effect of Ginsenoside-Rg combined with oxaliplatin and sorafenib on hepatic carcinoma cell apoptosis. Method Ginsenoside-Rg, oxaliplatin and sorafenib were divided into single drug group, two drugs group and three drugs group to act on hepatic carcinoma cell. Multiplication, prophase apoptosis, middle and advanced stage apoptosis were observed. Results To combine three drugs could improve hepatic carcinoma cell inhibition ratio, apoptosis ratio, apoptotic index compared to those of two drugs group or single drugs group(P<0.01). Conclusion To combine Ginsenoside-Rg, oxaliplatin and sorafenib can improve hepatic carcinoma cell inhibition ratio.
2.Effect of non finasteride on elderly male patients with chronic heart failure combined with benign prostatic hyperplasia
Haofei WANG ; Yunjuan HUANG ; Jianxun BAO ; Jianbo ZHAO
Chinese Journal of Primary Medicine and Pharmacy 2015;(10):1451-1453,1454
Objective To investigate clinical efficacy of finasteride on chronic heart failure(CHF)compli-cated with benign prostatic hyperplasia(BPH)in elderly patients.Methods 100 cases of elderly patients with CHF complicated with BPH were chosen,according to the number table method,they were divided into the observation group and control group,50 cases in each group,all patients were treated according to their cardiac function to regulate anti -CHF therapy.The patients in the observation group were added with finasteride treatment,the control group pla-cebo treated patients,the measurement indexes were compared between the two groups after treatment,including pros-tate volume,N terminal pro brain natriuretic peptide concentration,creatinine,international prostate symptom score and symptom score,need operation treatment intervention,incidence acute urinary retention rate.Results After treat-ment,the prostate volume,N terminal pro brain natriuretic peptide concentration,creatinine,international prostate symptom score of symptom scores of the observation group were (23.86 ±10.27)mL,(352.63 ±72.55 )g/L, (84.0 ±11.6)mol/L,(9.3 ±4.9),those in the control group were (39.11 ±12.53)mL,(483.46 ±76.47)g/L, (99.0 ±12.8)mol/L,(13.9 ±5.6).The difference was statistically significant(t =9.47,17.56,12.33,8.48,all P <0.05);the observation group need operation treatment intervention was 16.0%,obviously less than 52.0% in the control group,there was significant difference between two groups(χ2 =21.85,P <0.05);acute urinary retention in patients with the observation group the incidence rate of 14.0%,significantly lower than 38.0% in the control group, there was significant difference between two groups(χ2 =12.83,P <0.05).Conclusion Patients with CHF compli-cated with BPH aged at the same time standard anti heart failure treatment using finasteride,significantly reduce the prostate volume,reduce the measurement indexes,and significantly reduce the rate of operation intervention patients, safe and reliable,which is worthy of clinical application.
3.Flow-diverter devices in complex intracranial aneurysm: a complication analysis
Minghao YANG ; Jianxun TANG ; Bao CHEN ; Na LI ; Zhonghui YANG ; Ligang HU ; Jingfeng TANG
Chinese Journal of Neuromedicine 2023;22(11):1129-1135
Objective:To evaluate the complications of complex intracranial aneurysms after intervention with flow-diverter (FD) devices.Methods:Sixty patients with complex intracranial aneurysms accepted FD devices in Department of Cerebrovascular Diseases, Second Affiliated Hospital of Guilin Medical University from July 2018 to June 2021 were chosen. Clinical and imaging data of these patients were retrospectively analyzed, and complications were recorded: procedure-related adverse events, early postprocedural complications, complications during follow-up, and covered branch occlusion.Results:A total of 61 FD devices (47 Pipeline Flex, 10 Tubridge, 4 Surpass Streamline) were implanted in 60 patients. Incidence of procedure-related adverse events was 8.3% (5/60), including 3 with incomplete stent apposition, 1 with intraoperative bleeding, 1 with aneurysm neck not covered by stent; incidence of early postprocedural complications was 6.7% (4/60), including 3 with hemorrhagic complication and 1 with ischemic complication. DSA follow-up ([22.7±16.8] months) was completed in 54 patients; aneurysm healed rate was 83.3% (45/54). First DSA follow-up 6 months after surgery showed that in-stent restenosis was 7.4% (4/54), of which 2 deteriorated to parent vessel occlusion at 2- and 3-year after procedure, respectively. A total of 78 branch arteries were covered by FD devices, and only 1 (1.3%, 1/78) demonstrated branch artery occlusion at last follow-up, without clinical symptoms.Conclusion:The complications of complex intracranial aneurysms after intervention with FD devices should be recognized; incomplete stent apposition is the main procedure-related adverse event, and hemorrhagic complication mainly appear in the early postprocedural period; in-stent restenosis should be vigilant during follow-up.